Omeros Total Liabilities 2010-2024 | OMER

Omeros total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Omeros Annual Total Liabilities
(Millions of US $)
2023 $403
2022 $505
2021 $395
2020 $302
2019 $246
2018 $196
2017 $119
2016 $105
2015 $75
2014 $53
2013 $35
2012 $33
2011 $33
2010 $25
2009 $19
Omeros Quarterly Total Liabilities
(Millions of US $)
2024-06-30 $481
2024-03-31 $509
2023-12-31 $403
2023-09-30 $507
2023-06-30 $507
2023-03-31 $505
2022-12-31 $505
2022-09-30 $504
2022-06-30 $378
2022-03-31 $374
2021-12-31 $395
2021-09-30 $386
2021-06-30 $392
2021-03-31 $383
2020-12-31 $302
2020-09-30 $314
2020-06-30 $232
2020-03-31 $250
2019-12-31 $246
2019-09-30 $231
2019-06-30 $220
2019-03-31 $222
2018-12-31 $196
2018-09-30 $165
2018-06-30 $163
2018-03-31 $118
2017-12-31 $119
2017-09-30 $116
2017-06-30 $115
2017-03-31 $107
2016-12-31 $105
2016-09-30 $96
2016-06-30 $95
2016-03-31 $77
2015-12-31 $75
2015-09-30 $50
2015-06-30 $51
2015-03-31 $53
2014-12-31 $53
2014-09-30 $52
2014-06-30 $52
2014-03-31 $51
2013-12-31 $35
2013-09-30 $36
2013-06-30 $35
2013-03-31 $34
2012-12-31 $33
2012-09-30 $34
2012-06-30 $31
2012-03-31 $34
2011-12-31 $33
2011-09-30 $31
2011-06-30 $31
2011-03-31 $33
2010-12-31 $25
2010-09-30 $14
2010-06-30 $15
2010-03-31 $16
2009-12-31 $19
2009-09-30 $21
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.234B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $198.609B 25.65
Stryker (SYK) United States $139.112B 32.51
Boston Scientific (BSX) United States $123.274B 37.54
Medtronic (MDT) Ireland $114.744B 17.07
EssilorLuxottica (ESLOY) France $106.116B 0.00
Haleon (HLN) United Kingdom $47.707B 34.87
Lonza Group Ag (LZAGY) Switzerland $46.203B 0.00
ResMed (RMD) United States $35.702B 31.43
Koninklijke Philips (PHG) Netherlands $29.054B 22.08
Terumo (TRUMY) Japan $28.562B 40.34
Zimmer Biomet Holdings (ZBH) United States $21.656B 13.63
Baxter (BAX) United States $19.774B 13.41
Insulet (PODD) United States $16.665B 70.11
Smith & Nephew SNATS (SNN) United Kingdom $13.531B 0.00
Bio-Rad Laboratories (BIO) United States $9.604B 31.82
Demant (WILYY) Denmark $9.197B 0.00
BellRing Brands (BRBR) United States $7.682B 32.48
Lantheus Holdings (LNTH) United States $7.537B 18.09
ICU Medical (ICUI) United States $4.428B 42.25
TG Therapeutics (TGTX) United States $3.914B 41.44
Haemonetics (HAE) United States $3.842B 19.01
Neogen (NEOG) United States $3.799B 39.84
Perrigo (PRGO) Ireland $3.788B 11.97
GN Store Nord (GNNDY) Denmark $3.691B 22.23
Prestige Consumer Healthcare (PBH) United States $3.663B 18.25
Envista Holdings (NVST) United States $3.324B 17.73
QuidelOrtho (QDEL) United States $3.108B 19.59
Agios Pharmaceuticals (AGIO) United States $2.696B 0.00
Maravai LifeSciences Holdings (MRVI) United States $2.230B 0.00
Green Thumb Industries (GTBIF) United States $2.192B 36.79
LeMaitre Vascular (LMAT) United States $2.026B 54.00
AdaptHealth (AHCO) United States $1.520B 10.97
InMode (INMD) Israel $1.490B 9.49
Warby Parker (WRBY) United States $1.483B 0.00
AtriCure (ATRC) United States $1.403B 0.00
Owens & Minor (OMI) United States $1.237B 9.55
BioLife Solutions (BLFS) United States $1.187B 0.00
Verano Holdings (VRNOF) United States $1.110B 0.00
Evolus (EOLS) United States $1.037B 0.00
PetIQ (PETQ) United States $0.919B 23.30
Phibro Animal Health (PAHC) United States $0.908B 18.83
National Vision Holdings (EYE) United States $0.862B 27.40
Cresco Labs (CRLBF) United States $0.805B 0.00
Quanterix (QTRX) United States $0.594B 0.00
Surmodics (SRDX) United States $0.562B 119.39
ZimVie (ZIMV) United States $0.468B 43.49
VAREX IMAGING (VREX) United States $0.445B 13.43
Valneva SE (VALN) France $0.419B 0.00
Jin Medical (ZJYL) China $0.411B 0.00
Canopy Growth (CGC) Canada $0.401B 0.00
Cerus (CERS) United States $0.339B 0.00
TerrAscend (TSNDF) Canada $0.335B 0.00
Biote (BTMD) United States $0.331B 15.27
OraSure Technologies (OSUR) United States $0.324B 8.37
Aurora Cannabis (ACB) Canada $0.315B 0.00
Sanara MedTech (SMTI) United States $0.291B 0.00
Viemed Healthcare (VMD) United States $0.290B 31.08
Zynex (ZYXI) United States $0.264B 46.28
Utah Medical Products (UTMD) United States $0.236B 15.70
Ayr Wellness (AYRWF) United States $0.221B 0.00
MacroGenics (MGNX) United States $0.213B 0.00
Organigram Holdings (OGI) Canada $0.192B 0.00
High Tide (HITI) Canada $0.172B 71.33
Capricor Therapeutics (CAPR) United States $0.162B 0.00
FitLife Brands (FTLF) United States $0.154B 20.74
Brainsway (BWAY) Israel $0.137B 163.80
TriSalus Life Sciences (TLSI) United States $0.135B 0.00
Rockwell Medical (RMTI) United States $0.129B 0.00
Quipt Home Medical (QIPT) United States $0.122B 0.00
Veru (VERU) United States $0.117B 0.00
Fonar (FONR) United States $0.110B 11.15
Oramed Pharmaceuticals (ORMP) United States $0.101B 24.70
Jushi Holdings (JUSHF) United States $0.100B 0.00
Zevia PBC (ZVIA) United States $0.087B 0.00
InterCure (INCR) Israel $0.085B 14.31
Cytosorbents (CTSO) United States $0.077B 0.00
Safety Shot (SHOT) United States $0.076B 0.00
Cellectar Biosciences (CLRB) United States $0.076B 0.00
Modular Medical (MODD) United States $0.074B 0.00
MariMed (MRMD) United States $0.065B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.055B 3.62
Exagen (XGN) United States $0.050B 0.00
Allurion Technologies (ALUR) United States $0.041B 0.00
Apyx Medical (APYX) United States $0.038B 0.00
ImmuCell (ICCC) United States $0.028B 0.00
Meihua Medical Technologies (MHUA) China $0.026B 0.00
Nephros (NEPH) United States $0.019B 0.00
Flora Growth (FLGC) United States $0.019B 0.00
GlucoTrack (GCTK) United States $0.016B 0.00
Innovative Eyewear (LUCY) United States $0.016B 0.00
GUARDION HEALTH (GHSI) United States $0.014B 0.00
Trinity Biotech (TRIB) Ireland $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00
Agape ATP (ATPC) $0.007B 0.00
Sharps Technology (STSS) United States $0.007B 0.00
IM Cannabis (IMCC) Canada $0.005B 0.00
Leafly Holdings (LFLY) United States $0.005B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.001B 0.00
Senestech (SNES) United States $0.001B 0.00
Akanda (AKAN) United Kingdom $0.000B 0.00
United-Guardian (UG) United States $0.000B 20.48
SNDL (SNDL) Canada $0.000B 0.00